Spark Biomedical Inc.
Friendswood, TX
- UEI
- KUGZUDSCWQK5
- CAGE
- 891N8
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2319 Rymers Switch Cir, Friendswood, TX 77546, USA
- Website
- sparkbiomedical.com
- Founded
- 2018
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $575,086 |
| FY2023 | $574,689 |
Contract awards
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Cincinnati Univ Of | R34AA032824 | $40,071 | |
| University Of Texas Medical Branch At Galveston | RM1NS128787 | $214,709 | |
| Cincinnati Univ Of | UG3DA059409 | $11,132 | |
| Cincinnati Univ Of | UG3DA059409 | $46,568 | |
| Baylor College Of Medicine | P50FD006428 | $25,000 |
Similar vendors
About the company
Spark Biomedical Inc. is a self-certified small disadvantaged business and manufacturer of neuromodulation medical devices, specializing in transcutaneous auricular neurostimulation (TAN) technologies. The company focuses on developing innovative non-invasive neurological interventions for various medical conditions, with a primary emphasis on addressing withdrawal symptoms, stress reactions, and neurological performance challenges. Registered in SAM.gov since February 2019, Spark Biomedical operates as a corporate entity that provides advanced medical research and development solutions to federal agencies, particularly in the healthcare and medical research domains.
Through federal contract awards, Spark Biomedical has primarily worked with the Defense Health Agency and Army Medical Command on small business technology transfer (STTR) research contracts. The company has secured two notable STTR Phase I and Phase II contracts totaling approximately $1.3 million, specifically focused on developing military-grade wearable transcutaneous auricular neurostimulation devices designed to restore performance after acute stress reactions. These contracts were set aside for small businesses and demonstrated the company's expertise in creating innovative neurological intervention technologies for military personnel, leveraging their specialized knowledge in neuromodulation and performance enhancement.
Spark Biomedical has received multiple federal grants from the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, focusing on developing advanced technologies for treating substance withdrawal and related neurological conditions. The grants, totaling over $300,000, support research into transcutaneous auricular neurostimulation as a treatment for opioid withdrawal syndrome, alcohol use disorder, and developing machine learning algorithms to detect withdrawal symptoms and cravings. The company has also engaged in sub-grant collaborations with institutions like the University of Cincinnati and the University of Texas Medical Branch at Galveston, working on projects that explore improving treatment retention, understanding pain management mechanisms, and developing evidence-based treatments for complex neurological and substance-related disorders.
Quick answers
Is Spark Biomedical Inc. registered in SAM.gov?
Yes. Spark Biomedical Inc.'s SAM.gov registration is active through March 3, 2027.
How much has Spark Biomedical Inc. received in federal contracts?
Federal contracts obligated $1,149,775 to Spark Biomedical Inc. in fiscal years 2023 through 2027.
What is Spark Biomedical Inc.'s most recent federal award?
Spark Biomedical Inc.'s most recent federal grant award is Study of transcutaneous auricular neurostimulation as a treatment for alcohol use disorder (R41AA032157), from National Institute on Alcohol Abuse and Alcoholism (NIH), on September 1, 2025.
On GovTribe
See Spark Biomedical Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors